Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9599082 | 0.86 | HTT (0.42) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9599300 | 0.84 | SMN1; SMN2 (0.40) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9598136 | 0.83 | SMN1; SMN2 (0.39) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9599413 | 0.83 | L3MBTL1 (0.42) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL7265766 | 0.82 | KMT2A (0.37) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9597646 | 0.81 | ENPP1 (0.41) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9597622 | 0.79 | ENPP1 (0.38) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL4174907 | 0.79 | RAPGEF4 (0.39) | ENPP2HTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL9598810 | 0.79 | ENPP3 (0.44) | ENPP2HTTSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4171578 | 0.77 | HRH3 (0.37) | HTTSMN1; SMN2ALDH1A1L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0235111-B1 | INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1991-04-10 | — | — | EP | claimed |
| CN-101400349-A | Compounds that inhibit beta-amyloid production | ROSKAMP RES LLC (US) | 2009-04-01 | — | — | CN | disclosed |
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | ROSKAMP RESEARCH LLC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | ROSKAMP RESEARCH LLC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | ROSKAMP RESEARCH LLC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1993548-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | Roskamp Research LLC (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103683-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | ROSKAMP RESEARCH LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103683-A2 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION | ROSKAMP RESEARCH LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| US-5182291-A | Angina pectoris, hypotensive, antiarrhythmia, cerebral vascular insufficiency | SANOFI (FR) | 1993-01-26 | — | — | US | disclosed |
| US-5147878-A | Hypotensive, antiarrhythmia agents | SANOFI (FR) | 1992-09-15 | — | — | US | disclosed |
| US-5039700-A | Cardiovascular disorders, antitumor agents | SANOFI (FR) | 1991-08-13 | — | — | US | disclosed |
| US-5017579-A | Use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure | SANOFI (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4957925-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS, TREATMENT OF ANGINA | SANOFI (FR) | 1990-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | PSEN1, PSEN2, APP | ENPP2 322/4885HTT 52/4885SMN1; SMN2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.